Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

55
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

41
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

45
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
45
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation.

Journal of clinical medicine·2026
Same author

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same author

Early discharge and home treatment after acute pulmonary embolism.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention.

Internal and emergency medicine·2026
Same author

Impact of Left Bundle Branch Pacing on Left Ventricular Mechanical Efficiency.

Journal of cardiovascular electrophysiology·2026
Same author

Pulmonary embolism epidemiology: trends, risk factors, comorbidities, and clinical implications.

European heart journal·2026
Same journal

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same journal

"Reply to Murthy et al. regarding AI-derived LVOT-VTI for monitoring disease progression in transthyretin cardiac amyloidosis".

European journal of heart failure·2026
Same journal

High serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden in suspected ATTR cardiomyopathy.

European journal of heart failure·2026
Same journal

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.

European journal of heart failure·2026
Same journal

Time-dependent effects of interleukin-1 blockade by anakinra in myocarditis and inflammatory cardiomyopathy.

European journal of heart failure·2026
Same journal

Does Phenotypic Heterogeneity in Heart Failure With Preserved Ejection Fraction Imply Mechanistic Heterogeneity? The Myth of a Phenotype-Directed Therapeutic Framework and the Mandate for a Falsifiable Hypothesis.

European journal of heart failure·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

214

Heart failure-attributed mortality in Europe, 2012-2021.

Marco Zuin1,2,3, Pier Luigi Temporelli4, Marco Metra5

  • 1Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

European Journal of Heart Failure
|August 17, 2025
PubMed
Summary
This summary is machine-generated.

Heart failure mortality in Europe rose from 2012-2021, particularly in men and younger individuals. Significant regional differences in heart failure (HF) mortality trends highlight persistent disparities across Europe.

Keywords:
Heart failureMortalityTrend

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

4.4K

Related Experiment Videos

Last Updated: Sep 11, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

214
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

4.4K

Area of Science:

  • Cardiovascular Epidemiology
  • Public Health
  • Gerontology

Background:

  • Heart failure (HF) is a major global cause of cardiovascular mortality.
  • Comprehensive, up-to-date data on HF mortality trends in Europe are scarce.
  • Understanding these trends is crucial for public health interventions.

Purpose of the Study:

  • To analyze heart failure-attributed mortality trends in Europe from 2012 to 2021.
  • To investigate variations in these trends by age, sex, and geographic region.
  • To explore potential contributing factors to HF mortality.

Main Methods:

  • Utilized World Health Organization (WHO) mortality data (2012-2021).
  • Analyzed age-adjusted mortality rates (AAMRs) using joinpoint regression.
  • Examined trends in risk factors like obesity, diabetes, hypertension, and smoking.

Main Results:

  • Overall HF-attributable mortality increased by 0.4% annually (AAPC: +0.4%).
  • Mortality increased more significantly in men than women and in individuals under 70.
  • Mortality rates rose in Western, Eastern, and Northern Europe, but plateaued in Southern Europe.

Conclusions:

  • Heart failure-attributed mortality in Europe showed an upward trend between 2012 and 2021.
  • Significant disparities in HF mortality trends exist across different European regions and countries.
  • Rising obesity and diabetes prevalence may contribute to observed trends.